# MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC

Source: https://onco.cc/trials/nct05286957/  
OnCo record `nct05286957` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by The First Affiliated Hospital of Zhengzhou University, now recruiting.

## Summary

MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC is a phase 2, randomised interventional study registered as NCT05286957 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 60 participants, started 2022-06-20 and due to reach its primary completion in 2026-06-01. Interventions recorded: adjuvant tislelizumab and chemotherapy for MRD+ patients; adjuvant tislelizumab and chemotherapy for MRD+ patients; adjuvant chemotherapy for MRD- patients. Conditions listed: NSCLC. Primary outcome: 2-year PFS rate. Lung eligibility wording from the registry: "Histologically confirmed primary NSCLC, postoperative stage is IIA, IIB, IIIA or T3N2IIIB". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: Seagull
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05286957
- Phase: 2
- Setting: Minimal Residual Disease (MRD)-Guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB Non-small Cell Lung Cancer (NSCLC): a Randomized Controlled Phase II Study (Seagull)
- Sponsor: The First Affiliated Hospital of Zhengzhou University
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT05286957: https://clinicaltrials.gov/study/NCT05286957

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05286957.json